Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person These compounds are inhibitors of cytochrome P450 3A enzymes...
| Class:Id | Summation:9681849 |
|---|---|
| _displayName | These compounds are inhibitors of cytochrome P450 3A enzymes... |
| _timestamp | 2020-04-21 09:43:06 |
| created | [InstanceEdit:9681847] Jassal, Bijay, 2020-04-06 |
| modified | [InstanceEdit:9684395] Jassal, Bijay, 2020-04-21 |
| text | These compounds are inhibitors of cytochrome P450 3A enzymes (von Moltke et al. 1999, Yeo & Yeo 2001, Xu et al. 2010, Temesgen 2013, Greenblatt & Harmatz 2015). Cytochrome P450 3A4 (CYP3A4) is the most broadly active drug-metabolizing enzyme in humans. It oxidizes and clears over half of all administered pharmaceuticals due to its promiscuity. By inhibiting CYP3A4, these drugs can enhance bioavailability and prolong the plasma half-life of antiretroviral drugs such as those used to treat HIV infection. |
| (summation) | [Reaction:9678766] CYP3A4 binds CYP3A4 inhibitors [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by These compounds are inhibitors of cytochrome P450 3A enzymes... (9681849)
